CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.
February 14th 2021
The Bladder Cancer Advocacy Network's new podcast by, for, and about the bladder cancer community, "Bladder Cancer Matters," has a new episode available.
February 2nd 2021
In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.
January 30th 2021
The Bladder Cancer Advocacy Network (BCAN) announced that it is accepting applications for our 2021 Young Investigator Awards (YIAs).
January 26th 2021
BCAN is pleased to announce two 2021 Bladder Cancer Research Innovation Awards to support the work of investigators with exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding of the management of bladder cancer.
January 18th 2021
The Bladder Cancer Advocacy Network’s (BCAN’s) strong financial health and commitment to accountability and transparency have earned it a seventh consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This award puts BCAN in the top seven percent of all charities.
January 11th 2021
The Bladder Cancer Advocacy Network (BCAN) is pleased that the U.S. Senate voted overwhelmingly to approve the National Defense Authorization Act (NDAA) which contains a critical provision that will help veterans who were exposed to Agent Orange and later developed bladder cancer.
December 1st 2020
Predicting risk for recurrence and progression in patients with nonmuscle-invasive bladder cancer may help when discussing management options with clinicians.
September 30th 2020
Patients with advanced or metastatic bladder cancer, after responding to initial treatment with chemotherapy, may preserve their health improvements by starting immunotherapy immediately.
September 30th 2020
After treatment for bladder or prostate cancer, many survivors confront permanent sexual side effects. The good news is that treatments and psychological support are available.
July 1st 2020
The Food and Drug Administration approved Bavencio as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma.
June 16th 2020
"These results suggest that infigratinib has activity in patients with advanced urothelial carcinoma, regardless of the line of treatment,” says lead study author Dr. Yung Lyou.
June 12th 2020
At a median follow-up of 19.7 months, patients who received the combination achieved an objective response rate (the proportion of patients who had a complete or partial response to treatment) of 27%.
May 29th 2020
The immunotherapy Bavencio improves survival when given as a maintenance treatment in patients whose advanced urothelial carcinoma did not progress on platinum-based chemotherapy.
May 19th 2020
Even amid stay at home orders to mitigate the spread of the coronavirus, listen to your body and speak to your healthcare professionals when you are worried about a potential for cancer.
May 16th 2020
COVID-19 has drastically changed the landscape for patients with bladder cancer, but the new challenges are not insurmountable. CURE had the chance to interview the co-founder of the Bladder Cancer Advocacy Network to discuss these changes.
May 14th 2020
Amid the COVID-19 pandemic, the Bladder Cancer Advocacy Network is honoring Bladder Cancer Awareness Month in a slightly different way from previous years.
April 22nd 2020
The Food and Drug Administration’s approval of Jelmyto (mitomycin gel]) in low-grade upper tract urothelial cancer offers patients a much-needed treatment option, according to one expert.
April 17th 2020
Data from the phase 1b/2 trial of Padcev in combination with Keytruda displayed promise for patients with metastatic urothelial carcinoma, but further research is needed.
April 15th 2020
The Food and Drug Administration approved Jelmyto to treat patients with low-grade upper tract urothelial cancer.
April 14th 2020
Immunotherapy and targeted therapy medications have brought new hope to patients with advanced disease.
April 10th 2020
Using immunotherapy earlier, immediately after the conclusion of chemotherapy to treat metastatic bladder cancer, can delay the time until disease progression.
April 2nd 2020
A new study links e-cigarette use to bladder cancer but experts say more research is needed.
March 17th 2020
There are a number of treatment options available for patients with urothelial cancer, however, experts want to refine the current treatment paradigm amid new drugs entering the landscape.
February 23rd 2020
Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.
February 20th 2020
The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.
February 16th 2020
The combination of Padcev plus Keytruda induced a high rate of durable objective response rates in patients with locally advanced or metastatic urothelial cancer.
February 5th 2020
A new study supported the use of a blood test to detect clusters of cancer cells in the blood of asymptomatic individuals, meaning, patients could have a non-invasive screening and testing method.
January 29th 2020
Better response rates may be seen in patients with advanced bladder cancer when two therapies are combined.